What's Happening?
The FDA has granted accelerated approval to Boehringer Ingelheim's drug Hernexeos for treating patients with unresectable or metastatic non-small cell lung cancer with specific mutations. This approval is part of the FDA's Commissioner’s National Priority
Voucher (CNPV) program, which aims to expedite drug reviews by reducing the typical review time from 10-12 months to 1-2 months. Hernexeos is the second drug to receive approval under this program, following USAntibiotics' Augmentin XR. The approval was based on data from the Phase 1b Beamion LUNG-1 study, which showed a 76% overall response rate in treatment-naïve patients. The drug, a kinase blocker targeting HER2, was previously approved for patients with HER2-mutated NSCLC and now expands to those untreated.
Why It's Important?
The approval of Hernexeos under the CNPV program highlights the FDA's commitment to accelerating the availability of treatments for serious conditions like lung cancer. This program is significant as it aligns with national priorities and provides a faster pathway for drug approvals, potentially benefiting patients who require urgent treatment options. The program's efficiency is demonstrated by the rapid approval timeline, which could set a precedent for future drug approvals. However, the program has faced criticism for its lack of transparency, as noted by Rep. Jake Auchincloss, raising concerns about the decision-making process within the FDA.
What's Next?
Boehringer Ingelheim will need to conduct a confirmatory study to validate the clinical benefits of Hernexeos to maintain its approval. The success of this program may encourage other pharmaceutical companies to pursue similar expedited pathways for their drugs. Additionally, the FDA may face increased scrutiny and pressure to ensure transparency and accountability in its approval processes, especially under the CNPV program.
